This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
Male or female ages 18 to 70 years at screening
HDV RNA ≥ 500 IU/mL at screening
Receiving BLV 2 mg SC QD for ≥ 24 weeks at Day 1
Noncirrhotic or compensated cirrhotic liver disease at screening
Serum ALT ≥ 5 × ULN
Any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation.
History of significant liver disease from non-HBV or non-HDV etiology
History of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients.